Collegium Pharma guides FY2026 revenue $805-825M; Jornay PM $190-200M; adj. EBITDA $455-475M

COLLEGIUM PHARMACEUTICAL, INC

Product revenue guidance $805-825M; Jornay PM net revenue $190-200M.
Adjusted EBITDA guidance $455-475M, flat versus raised 2025 midpoint.
Closed $980M syndicated credit facility; repaid $581M Pharmakon term loan, expects annualized interest savings.
Signed supply/quality agreements with Hikma for authorized generics of Nucynta/Nucynta ER; AG Nucynta ER launch expected Q1 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.